Atara Biotherapeutics (NASDAQ:ATRA) CAO Yanina Grant-Huerta Sells 2,414 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 2,414 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $9.13, for a total transaction of $22,039.82. Following the completion of the transaction, the chief accounting officer owned 49,636 shares in the company, valued at $453,176.68. The trade was a 4.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Price Performance

Shares of NASDAQ:ATRA traded up $0.04 during midday trading on Wednesday, hitting $9.45. The company had a trading volume of 80,398 shares, compared to its average volume of 1,179,400. The company has a market cap of $85.14 million, a price-to-earnings ratio of -14.10 and a beta of -0.30. Atara Biotherapeutics, Inc. has a 12-month low of $3.92 and a 12-month high of $19.15. The company has a fifty day moving average of $5.92 and a two-hundred day moving average of $9.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. Research analysts expect that Atara Biotherapeutics, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors have recently bought and sold shares of ATRA. Raymond James Financial Inc. purchased a new stake in Atara Biotherapeutics in the 2nd quarter worth $31,000. Dimensional Fund Advisors LP purchased a new stake in Atara Biotherapeutics in the 4th quarter worth $181,000. Walleye Capital LLC purchased a new stake in Atara Biotherapeutics in the 4th quarter worth $220,000. Marshall Wace LLP purchased a new stake in Atara Biotherapeutics in the 2nd quarter worth $327,000. Finally, Quadrature Capital Ltd increased its stake in Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after buying an additional 3,779 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Key Atara Biotherapeutics News

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Freedom Capital upgraded Atara Biotherapeutics from “strong sell” to “hold,” which can support sentiment by signaling less bearish expectations for the company. Read More
• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Levi & Korsinsky, Pomerantz, Bronstein, and The Gross Law Firm, announced or renewed notices about a class-action lawsuit and the May 22, 2026 deadline for investors to seek lead-plaintiff status. These updates do not change fundamentals directly, but they keep legal risk and investor uncertainty in focus. Article Title
• Neutral Sentiment: The repeated class-action announcements allege securities-law violations and seek damages for investors who bought Atara shares during the specified class period, reinforcing an existing legal overhang rather than introducing a new operational development. Article Title

Analysts Set New Price Targets

Several equities research analysts have recently commented on ATRA shares. Freedom Capital upgraded Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Wall Street Zen upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.